HighTide Therapeutics Hong Kong Ltd (Ticker: 2511 HK) is a Hong Kong-based biopharmaceutical company with a focus on metabolic and digestive diseases. The company pipeline includes treatments for conditions such as nonalcoholic steatohepatitis (NASH), type 2 diabetes (T2DM), severe hypertriglyceridemia (SHTG), primary sclerosing cholangitis (PSC), and primary biliary cholangitis (PBC). Their lead drug candidate, HTD1801, has received Fast Track designation from the U.S. FDA in 2018 for both NASH and PSC, as well as Orphan Drug designation for PSC.

HighTide Therapeutics is planning to list on the Hong Kong Stock Exchange on December 22, 2023. The company is offering 24.19 million shares at an offer price of HKD 11.50 per share, aiming to raise HKD 278.23 million (USD 35.63 million). The expected market capitalization at offer is HKD 5.92 billion (USD 758.10 million). The offering is managed by a consortium of underwriters including BOCOM International Securities Ltd, CCB International Capital Ltd, and others.